Rheumatoid arthritis: Treating to target with disease-modifying drugs

British Journal of Nursing

Volumn 20, Issue 19, 2011, Pages 1240-1245

  Firth, Jill ^a  

^a Pennine Musculoskeletal Partnership Ltd   (United Kingdom)

Author keywords

Diseasemodifying anti rheumatic drugs; DMARDs; Rheumatoid arthritis; Treating to target

Indexed keywords

EID: 80054987718     PISSN: 09660461     EISSN: None     Source Type: Journal    
DOI: 10.12968/bjon.2011.20.19.1240     Document Type: Article

References (25)

1. Bakker M F, Jacobs J W, Welsing PM et al (2010) Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheumc Dis 69(10):1849-52
2. British National Formulary (2011) British National Formulary website. http://bnf.org/bnf/index.htm (Accessed 19 October 2011)
3. Brown SJ, McCabe CS, Hewlett S et al (2006) Rheumatology telephone helplines: patient and health professionals' requirements. Musculoskeletal Care 4(1):24-37
4. Chakravarty K, McDonald H, Pullar T et al (2008) BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology 47(6):924-5 Epub
5. Choy EH, Smith C, Doré CJ, Scott DL (2005) A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 44(11):1414-21 Epub (Pubitemid 41631866)
6. Creemers MCW, van de Putte LBA (2004) Rheumatoid arthritis - the clinical picture. In: Isenberg DA, Maddison PJ, Woo P, Glass D, Breedveld FC. eds, Oxford Textbook of Rheumatology. Oxford University Press, Oxford
7. Dale J, Alcorn N, Capell H, Madhok R (2007) Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nat Clin Pract Rheumatol 3(8):450-8 (Pubitemid 47193551)
8. Dale J, Porter D (2010) Pharmacotherapy: concepts of pathogenesis and emerging treatments. Optimising the strategy of care in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 24(4):443-55
9. Datapharm Communications Ltd (2011) The electronic Medicines Compendium website. http://www.medicines.org.uk/emc/ (Accessed 19 October 2011)
10. Firth J (2011) Rheumatoid arthritis: diagnosis and multidisciplinary management. Br J Nurs 20 (18) 1179-85
11. Grondal L, Tengstrand B, Nordmark B, Wretenberg P, Stark A (2008) The foot: still the most important reason for walking incapacity in rheumatoid arthritis: distribution of symptomatic joints in 1, 000 RA patients. Acta Orthop 79(2):257-61 (Pubitemid 351878358)
12. Hameed B, Jones H (2010) Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis. Int J Rheum Dis 13(4):e83-4
13. Hill J, Bird H, Johnson S (2001) Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 60(9):869-75 (Pubitemid 32778177)
14. Hui M, Ding T, Deighton C (2010) An update on DMARDs and biologics. http://tinyurl.com/3zc6yof (Accessed 20 October 2011)
15. Katchamart W, Trudeau J, Phumethum V, Bombardier C (2010) Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev 14(4):CD008495
16. Luqmani R, Hennell S, Estrach C et al (2006) British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology 45(9):1167-9 Epub (Pubitemid 44542111)
17. National Institute for Health and Clinical Excellence (2009) Rheumatoid arthritis: the management of rheumatoid arthritis in adults. http://tinyurl.com/66xcdqg (Accessed 19 October 2011)
18. National Rheumatoid Arthritis Society (2011) National Rheumatoid Arthritis Societ website. www.nras.org.uk (Accessed 19 October 2011)
19. O'Mahony R, Richards A, Deighton C, Scott D (2010) Withdrawal of diseasemodifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 69(10):1823-6 Epub
20. Schoels M, Knevel R, Aletaha D et al (2010) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 69(4):638-43
21. Smolen JS, Aletaha D, Bijlsma JW et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4):631-7 Epub
22. van der Heijde DM, van't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van De Putte LB (1992) Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51(2):177-81
23. Whalley D, McKenna S P, de Jong Z, van der Heijde D (1997) Quality of life in rheumatoid arthritis. Br J Rheumatol 36(8):884-8
24. Wong M, Mulherin D (2007) The influence of medication beliefs and other psychosocial factors on early discontinuation of disease-modifying anti-rheumatic drugs. Musculoskeletal Care 5(3):148-59
25. Young A, Koduri G (2007) Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract Res Clin Rheumatol 21(5):907-27 (Pubitemid 47377809)